Correction to “The Quest for Secondary Pharmaceuticals: Drug Repurposing/Chiral-Switches Combination Strategy”

Page 209, bottom of left column. Dr. Sheila DeWitt (DeuteRx, LLC, Bedford, NH, USA; email: sdewitt@deuterx.com) has recently drawn our attention to a mistake in the following sentence: “The deuterated S-enantiomer of lenalidomide DP-053 (formerly CTP-221, Figure 2) was shown to be ‘greatly stabilized to epimerization and results in a more desirable pharmacokinetic profile than racemic lenalidomide’ ¹¹⁵ (see also ref 108, ref 56 therein).” There was also a mistake in ref 115 that was cited in that text, which is corrected in ref (1) herein. DP-053 was not formerly CTP-221. They are two different compounds that were pursued separately by Deuteria Pharmaceuticals, Inc. and Concert Pharmaceuticals, Inc., respectively. DP-053 is the structure shown in Figure 2 (D1-S-lenalidomide) which was pursued by Deuteria Pharmaceuticals, Inc. Celgene Corporation (now Bristol-Myers Squibb Company) acquired Deuteria and selected assets, including DP-053, in December 2012. The remaining assets were spun-out into DeuteRx, LLC. CTP-221 is D5-S-lenalidomide, which was pursued by Concert Pharmaceuticals, Inc. and then part of a development and license agreement with Celgene Corporation (now Bristol-Myers Squibb Company) in May 2013. The text should have stated that “CTP-221 was shown to be ‘greatly stabilized to epimerization and results in a more desirable pharmacokinetic profile than racemic lenalidomide’ ¹¹⁵ (see also ref 108, ref 56 therein).” We apologize for the above-mentioned mistakes. Other data shown in the published Perspective are correct, and this modification does not affect the overall conclusions of our study. We thank Dr. Sheila DeWitt for drawing our attention to these mistakes and for giving us the opportunity to correct them. This article references 1 other publications. Corrected ref 115 from the published Perspective: This article has not yet been cited by other publications.